Skip to main content

Market Overview

Takeda Divests Four Diabetes Products In Japan To Teijin Pharma

  • Takeda Pharmaceutical Co Ltd (NYSE: TAKwill sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1.25 billion).
  • The portfolio generated total sales of approximately ¥30.8 billion (roughly $290 million) in FY2019.
  • Takeda will continue to manufacture and supply these products.
  • Takeda will use the proceeds to pay down debt and accelerate deleveraging towards its target of 2x net debt/adjusted EBITDA within FY2021 – FY2023.
  • Takeda said that the divestiture provides momentum toward optimizing its portfolio for growth primarily focused on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience.
  • Takeda has announced 12 deals since January 2019, for a total aggregate value of up to approximately $12.9 billion.
  • Price Action: TAK at $16.75 closed 2.7% lower on Thursday. 

Related Articles (TKPHF + TAK)

View Comments and Join the Discussion!

Posted-In: DivestituresBiotech M&A News Health Care Asset Sales General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at